Management of newly diagnosed immune thrombocytopenia

Can we change outcomes?

Cindy E Neunert

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the platelet count, prevention of bleeding, and inducing remission. Current standard first-line therapy is a course of corticosteroids. Although this treatment paradigm increases the platelet count in the majority of patients, a high percentage relapse after discontinuation of corticosteroid therapy. For this reason, intensification of first-line therapy that results in superior long-term remission rates would be desirable. This manuscript focuses primarily on adults with idiopathic thrombocytopenic purpura (ITP), highlighting pediatric data and practice when applicable. The primary aim is to outline upfront strategies for treatment-naive patients with ITP to enhance remission rates, taking into account assessment of the risks and benefits of these approaches.

Original languageEnglish (US)
Pages (from-to)400-405
Number of pages6
JournalHematology
Volume2017
Issue number1
DOIs
StatePublished - Dec 8 2017

Fingerprint

Idiopathic Thrombocytopenic Purpura
Platelet Count
Adrenal Cortex Hormones
Blood Platelets
Therapeutics
Thrombocytopenia
Pediatrics
Hemorrhage
Recurrence
Antibodies

ASJC Scopus subject areas

  • Hematology

Cite this

Management of newly diagnosed immune thrombocytopenia : Can we change outcomes? / Neunert, Cindy E.

In: Hematology, Vol. 2017, No. 1, 08.12.2017, p. 400-405.

Research output: Contribution to journalArticle

Neunert, Cindy E. / Management of newly diagnosed immune thrombocytopenia : Can we change outcomes?. In: Hematology. 2017 ; Vol. 2017, No. 1. pp. 400-405.
@article{dc500ba2b06545b3984dd6c45ff0ef84,
title = "Management of newly diagnosed immune thrombocytopenia: Can we change outcomes?",
abstract = "Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the platelet count, prevention of bleeding, and inducing remission. Current standard first-line therapy is a course of corticosteroids. Although this treatment paradigm increases the platelet count in the majority of patients, a high percentage relapse after discontinuation of corticosteroid therapy. For this reason, intensification of first-line therapy that results in superior long-term remission rates would be desirable. This manuscript focuses primarily on adults with idiopathic thrombocytopenic purpura (ITP), highlighting pediatric data and practice when applicable. The primary aim is to outline upfront strategies for treatment-naive patients with ITP to enhance remission rates, taking into account assessment of the risks and benefits of these approaches.",
author = "Neunert, {Cindy E}",
year = "2017",
month = "12",
day = "8",
doi = "10.1182/asheducation-2017.1.400",
language = "English (US)",
volume = "2017",
pages = "400--405",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Management of newly diagnosed immune thrombocytopenia

T2 - Can we change outcomes?

AU - Neunert, Cindy E

PY - 2017/12/8

Y1 - 2017/12/8

N2 - Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the platelet count, prevention of bleeding, and inducing remission. Current standard first-line therapy is a course of corticosteroids. Although this treatment paradigm increases the platelet count in the majority of patients, a high percentage relapse after discontinuation of corticosteroid therapy. For this reason, intensification of first-line therapy that results in superior long-term remission rates would be desirable. This manuscript focuses primarily on adults with idiopathic thrombocytopenic purpura (ITP), highlighting pediatric data and practice when applicable. The primary aim is to outline upfront strategies for treatment-naive patients with ITP to enhance remission rates, taking into account assessment of the risks and benefits of these approaches.

AB - Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the platelet count, prevention of bleeding, and inducing remission. Current standard first-line therapy is a course of corticosteroids. Although this treatment paradigm increases the platelet count in the majority of patients, a high percentage relapse after discontinuation of corticosteroid therapy. For this reason, intensification of first-line therapy that results in superior long-term remission rates would be desirable. This manuscript focuses primarily on adults with idiopathic thrombocytopenic purpura (ITP), highlighting pediatric data and practice when applicable. The primary aim is to outline upfront strategies for treatment-naive patients with ITP to enhance remission rates, taking into account assessment of the risks and benefits of these approaches.

UR - http://www.scopus.com/inward/record.url?scp=85038427216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038427216&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2017.1.400

DO - 10.1182/asheducation-2017.1.400

M3 - Article

VL - 2017

SP - 400

EP - 405

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

IS - 1

ER -